MedTrace Logo

Study of Antithrombotic Treatment After IntraCerebral Haemorrhage

NCT03186729 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 134

Last updated 2025-02-12

No results posted yet for this study

Summary

The study evaluates the effects of antithrombotic drugs (anticoagulant drugs or antiplatelet drugs) for prevention of ischaemic events in patients With recent intracerebral haemorrhage.

Conditions

  • Cerebral Hemorrhage
  • Intracranial Hemorrhages
  • Atrial Fibrillation
  • Anticoagulant-Induced Bleeding
  • Secondary Prevention

Interventions

DRUG

Antithrombotic Agent

Anticoagulant or antiplatelet drugs

Sponsors & Collaborators

  • Oslo University Hospital

    lead OTHER

Principal Investigators

  • Torgeir Bruun Wyller, PhD · Oslo University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-01
Primary Completion
2024-08-31
Completion
2024-08-31
FDA Drug
Yes

Countries

  • Denmark
  • Norway
  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03186729 on ClinicalTrials.gov